Strength, Aging, and Memory in Prostate Cancer

University of Nebraska20 enrolled

Overview

The objective of this study is to compare changes in neurocognitive function across a 12-month period between three groups: (1) men treated with androgen deprivation therapy (ADT) for prostate cancer (PCa); (2) men under active surveillance for PCa; and (3) men without a history of cancer.

Aim 1: This study will examine differences in neurocognitive function (cognitive performance, brain structural integrity) from baseline (within 30 days of ADT initiation or 90 days of diagnosis) to 6- and 12-month follow-up. Aim 2: Examine group differences in components of frailty (e.g., lean mass, muscle strength, physical function, fatigue, physical activity) from baseline to 6- and 12-month follow-up. Men will be recruited for this study if they are (1) recently diagnosed with PCa and scheduled to receive 6-months or more of ADT (ADT+ group, n=20), (2) recently diagnosed with PCa and under active surveillance (ADT- group, n=20), or (3) healthy men without a history of cancer (PCa- group, n=20). Eligible men (N=60) will be scheduled for two or three testing appointments at each testing timepoint. To assess Aim 1, participants will complete measures at baseline (M0), 6-month follow-up (M6), and 12-month follow-up (M12). Aim 1 measures include: neurocognitive tasks, functional magnetic resonance imaging (optional; n=10 ADT+ and n=10 ADT- only), and questionnaires. To assess Aim 2, outcomes indicated as components of frailty syndrome will be measured, including: dual-energy X-ray absorptiometry (e.g., appendicular lean mass), upper and lower body dynamometry, physical function and functional capacity, questionnaires (i.e., fatigue surveys), and physical activity monitoring (i.e., accelerometry). Findings from this study will build upon the scientific framework for the potential frailty pathway of cancer-associated cognitive decline in PCa patients in order to develop future evidence-based interventions to manage cognitive impairment in men diagnosed with PCa.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Prostate Neoplasm Prostate Cancer

Eligibility

Sex: MALEMin age: 19 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Telephone Interview of Cognitive Status (TICS-M) performance above impaired range (≥21) Group-specific criteria: * First time, primary diagnosis of prostate cancer (ADT+ and ADT-) * Diagnosed within past 30 days (ADT-) * Scheduled to receive ≥ 6-months androgen deprivation therapy and have not received \>30 days of androgen deprivation therapy (ADT+) * Men without a history of cancer who are within one year of age of ADT+ participants (PCa-) Exclusion Criteria: * Second cancer diagnosis (excluding non-invasive skin cancers) * History of stroke, transient ischemic attack, neurological disorder, or brain surgery involving tissue removal * Unable to walk without assistance * Unwilling to complete study requirements * Body weight greater than 300 pounds (DXA requirement) * Moderate-intensity physical activity ≥ 150 minutes per week * Upper and lower body strength training ≥ 2 days per week * Unable to read in English

Locations (1)

University of Nebraska Medical Center

Omaha, Nebraska, United States

Outcomes

Primary Outcomes

Change in inhibitory control

Change in interference score on Stroop task, with negative values indicating lower inhibitory control. The Stroop task interference score is a continuous variable with no minimum or maximum value.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in cognitive flexibility

Change in reaction time on Task-switch task, with higher values indicating lower cognitive flexibility. The Task-switch reaction time is a continuous variable with no minimum or maximum value.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in executive function

Change in completion time on Trails B task, with higher values indicating lower executive function. Trails B completion time is a continuous variable with no minimum or maximum value.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in spatial working memory reaction time

Change in reaction time on spatial working memory task, with faster reaction times indicating better spatial working memory.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in short term memory

Change in accuracy on N-Back task, with higher accuracy indicating better short-term memory.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in processing speed

Change in accuracy on Attentional Blink task, with higher accuracy indicating faster processing speed.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in verbal memory

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Secondary Outcomes

Change in appendicular lean mass index

Change in appendicular lean mass index (ALMI) as measured by dual-energy X-ray absorptiometry (DXA) with higher scores indicating more lean mass. Appendicular lean mass, as measured by DXA, will be divided by height to determine ALMI. ALMI score is a continuous variable with no minimum or maximum value.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in physical function

The Short Physical Performance Battery (SPPB) will be used to assess physical function. Higher scores on the SPPB are indicative of better physical function. The SPPB has a minimum score of 0 and a maximum score of 12.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in functional capacity

The Six Minute Walk Test (6MWT) will be used to measure functional capacity. The 6MWT is scored as distance walked in the 6 minutes with greater distance indicating greater functional capacity.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in upper body strength

Change in grip strength as measured by hand grip dynamometry with higher scores indicating greater upper body strength. Hand grip strength is a continuous variable with no minimum or maximum value.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in lower body strength

Change in quadriceps strength as measured by hand-held quadriceps dynamometry with higher scores indicating greater lower body strength. Quadriceps strength is a continuous variable with no minimum or maximum value.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in physical activity

Change in daily minutes of moderate to vigorous physical activity (MVPA) will be measured via accelerometry with more minutes of daily MVPA indicating more physical activity.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)

Change in cancer-related fatigue

The Functional Assessment in Chronic Illness Therapy (FACIT) - Fatigue Scale will be used to measure cancer-related fatigue. Scores range from 0-52, with higher scores indicating less cancer-related fatigue.

Time frame: Baseline (M0), 6-month follow-up (M6), 12-month follow-up (M12)